Study of Sorafenib and Transarterial Chemoembolization (TACE) versus TACE to Treat Advanced Hepatocellular Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 21 May 2012
At a glance
- Drugs Sorafenib (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- 21 May 2012 Planned end date (Mar 2018) added as reported by Chinese Clinical Trial Register record.
- 09 Jan 2012 Planned number of patients changed to 360.
- 09 Jan 2012 New trial record